Berkshire’s new boss is overseeing a concentrated portfolio, with $255 billion invested across seven proven winners.
Keybanc analyst Jason Celino maintains JFrog (NASDAQ:FROG) with a Overweight and raises the price target from $114 to $118.
Senstar Technologies (NASDAQ:SNT) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call ha...
Discover how policy shifts, jobs data, and energy prices are reshaping AI data centers, S&P 500 earnings, and Fed outlooksâclick to read the analysi...
Southern Company has underperformed the broader market over the past year, and analysts remain unsure about the stock’s prospects.
Elon Musk claims SoftBank is defaulting on turbine orders as financing questions grow around its Stargate buildout
Piper Sandler analyst Jessica Tassan maintains Oscar Health (NYSE:OSCR) with a Overweight and lowers the price target from $48 to $45.
RenovoRx, Inc. (RNXT) Q3 2026 Earnings Call November 5, 2026 4:30 PM ESTCompany ParticipantsStephanie Carrington - Managing DirectorShaun Bagai - CEO,...
IREN Limited is executing on massive ARR growth with $4B targeted by just January 2027. I rate IREN stock as Strong Buy. Click to read my full update ...
Kura Sushi USA, Inc. (KRUS) Q4 2026 Earnings Call November 5, 2026 5:00 PM ESTCompany ParticipantsBenjamin Porten - Senior Vice President of Investor....
https://www.sec.gov/Archives/edgar/data/1896212/000175392626002067/corres.htm
Piper Sandler analyst Adam Maeder maintains iRhythm Holdings (NASDAQ:IRTC) with a Overweight and lowers the price target from $160 to $150.
DraftKings (NASDAQ:DKNG) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call has been pr...
Iovance reaffirms its 2026 revenue outlook as Q3 sales jump 80%, fueled by Amtagvi adoption, improving margins and progress in its cancer pipeline.
Keybanc analyst Jackson Ader maintains Five9 (NASDAQ:FIVN) with a Overweight and raises the price target from $32 to $34.
Meta Platforms is rated Buy, with shares ~20% below peak and long-term pricing power supporting heavy spending. Read more on META stock here.
Piper Sandler analyst David Amsellem maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Neutral and lowers the price target from $43 to $28.
OCTV scores Technical Rating 7 and Setup Quality 9, signaling a tight breakout setup with defined entry/exit despite weak relative strength.
Charter Communications (NASDAQ:CHTR) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call...
Loading...
